Comparative Pharmacology
Head-to-head clinical analysis: ZANTAC 300 versus ZANTAC IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZANTAC 300 versus ZANTAC IN PLASTIC CONTAINER.
ZANTAC 300 vs ZANTAC IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
300 mg orally once daily at bedtime or 150 mg orally twice daily.
150 mg orally twice daily or 50 mg intravenously every 6 to 8 hours.
None Documented
None Documented
Approximately 2.5–3 hours in patients with normal renal function; prolonged in renal impairment (creatinine clearance <30 mL/min: up to 6–12 hours).
Terminal elimination half-life: 2.5–3 hours; prolonged to 4–5 hours in elderly or moderate renal impairment; accumulates in severe renal failure (CrCl <10 mL/min).
Renal (approximately 30% unchanged active drug via tubular secretion and glomerular filtration); hepatic metabolism to N-oxide, S-oxide, and desmethyl metabolites (about 70% of dose); fecal excretion (minor, <5%).
Renal: 70% (unchanged drug); Hepatic metabolism: 30% (minor N-oxide, S-oxide, and desmethyl metabolites); Biliary/fecal: negligible.
Category C
Category C
H2 Antagonist
H2 Antagonist